Biomea Fusion (BMEA) Change in Account Payables (2020 - 2026)
Biomea Fusion (BMEA) posted Change in Account Payables of $1.4 million for Q1 2026, up 143.55% sequentially from -$3.2 million in Q4 2025, and up 126.44% YoY from $609441.6 in Q1 2025.
Biomea Fusion (BMEA) Change in Account Payables (2020 - 2026) Analysis & Trends
Biomea Fusion has reported Change in Account Payables for 7 years, with the latest figure at $1.4 million in Q1 2026.
- Quarterly Change in Account Payables rose 126.44% year-over-year to $1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.1 million (down 201.84% YoY) and the FY2025 annual result came in at -$9.7 million, down 259.33% from the prior year.
- Change in Account Payables rose to $1.4 million in Q1 2026 per BMEA's latest filing, from -$3.2 million in the prior quarter.
- Over five years, Change in Account Payables peaked at $4.0 million in Q4 2024 and troughed at -$5.2 million in Q1 2025.
- A 5-year average of $193529.4 and a median of $517000.0 in 2025 frame the typical range for Change in Account Payables.
- The widest YoY moves for Change in Account Payables: up 2814.63% in 2022, down 701.1% in 2022.
- Over 5 years, Change in Account Payables stood at $3.0 million in 2022, then climbed by 23.14% to $3.7 million in 2023, then advanced by 9.81% to $4.0 million in 2024, then tumbled by 178.83% to -$3.2 million in 2025, then jumped by 143.55% to $1.4 million in 2026.
- According to Business Quant data, Change in Account Payables over the past three periods registered $1.4 million, -$3.2 million, and -$1.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Biomea Fusion | 97.69 Mn | 97.69 Mn | - | -1.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.31 Mn |
| Jun 30, 2026 | -1.31 Mn |
| Mar 31, 2026 | 1.38 Mn |
| Mar 31, 2026 | 1.38 Mn |
| Dec 31, 2025 | -3.17 Mn |
| Dec 31, 2025 | -3.17 Mn |
| Sep 30, 2025 | -1.83 Mn |
| Sep 30, 2025 | -1.83 Mn |
| Jun 30, 2025 | 517,000.00 |
| Jun 30, 2025 | 517,000.00 |
| Mar 31, 2025 | -5.22 Mn |
| Mar 31, 2025 | -5.22 Mn |
| Dec 31, 2024 | 4.02 Mn |
| Dec 31, 2024 | 4.02 Mn |
| Sep 30, 2024 | 3.13 Mn |
| Sep 30, 2024 | 3.13 Mn |
| Jun 30, 2024 | 1.12 Mn |
| Jun 30, 2024 | 1.12 Mn |
| Mar 31, 2024 | -2.18 Mn |
| Mar 31, 2024 | -2.18 Mn |